{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:30:28Z","timestamp":1793917828762,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.radonc.2025.111292","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:47:24Z","timestamp":1763650044000},"page":"111292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Radiotherapy dose\u2013response of mycosis fungoides with large cell transformation"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-3159","authenticated-orcid":false,"given":"Martin J.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-1343","authenticated-orcid":false,"given":"Stephen","family":"Lade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friyana","family":"Bhabha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odette","family":"Buelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8723","authenticated-orcid":false,"given":"Belinda A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111292_b0005","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111292_b0010","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111292_b0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0020","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0025","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.radonc.2025.111292_b0035","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.20225","article-title":"Large-cell transformation of mycosis fungoides: patterns of care and patient outcomes","volume":"207","author":"Johnstone","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.radonc.2025.111292_b0040","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-stage mycosis fungoides and S\u00e9zary syndrome: Survival and response to treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.radonc.2025.111292_b0045","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.radonc.2025.111292_b0050","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0055","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clml.2020.05.001","article-title":"Outcomes of patients with transformed mycosis fungoides: Analysis from a prospective multicenter US cohort study","volume":"20","author":"Lansigan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.radonc.2025.111292_b0060","unstructured":"National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 Mycosis Fungoides\/Sezary Syndrome. Accessed December 17, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf."},{"key":"10.1016\/j.radonc.2025.111292_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115064","article-title":"Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group","volume":"212","author":"Elsayad","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111292_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semradonc.2024.08.005","article-title":"Breaking down the barriers for patients with cutaneous T-cell lymphoma: current controversies and challenges for radiation oncologists in 2024","volume":"35","author":"Campbell","year":"2025","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2025.111292_b0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijrobp.2024.11.011","article-title":"Real-world pattern-of-care analysis of primary cutaneous lymphomas radiation therapy among European Organisation for Research and treatment of Cancer members","volume":"121","author":"Elsayad","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111292_b0080","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions staging classification mycosis fungoides Sezary syndrome: proposal International Society Cutaneous Lymphomas (ISCL) cutaneous lymphoma task force European Organization Research Treatment Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0085","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.111292_b0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.radonc.2025.111292_b0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"International lymphoma radiation oncology group. modern radiation therapy primary cutaneous lymphomas: field dose guidelines from international lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111292_b0100","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/ajd.13467","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Australian clinical practice statement","volume":"62","author":"Bhabha","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.radonc.2025.111292_b0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.radonc.2025.111292_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111292_b0115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.radonc.2025.111292_b0120","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies","volume":"7","author":"Campbell","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2025.111292_b0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/annonc\/mdy207","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium","volume":"30","author":"Quaglino","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2025.111292_b0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ijrobp.2025.07.054","article-title":"Radiation therapy utilization for primary cutaneous T-cell lymphoma is lowest among patients living in the most geographically accessible areas: An Australian study","volume":"123","author":"Campbell","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111292_b0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome patients treated single- fraction dose palliative radiation cutaneous T-cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"10.1016\/j.radonc.2025.111292_b0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111292_b0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.21873\/anticanres.13105","article-title":"Cutaneous T-cell lymphoma: trends in radiation doses and patterns of care 2004-2015","volume":"39","author":"Miccio","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2025.111292_b0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.prro.2023.03.015","article-title":"Single-fraction radiation therapy for localized cutaneous T-cell lymphoma","volume":"13","author":"Wang","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111292_b0155","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.prro.2022.10.004","article-title":"Optimizing palliative focal radiation therapy dose in cutaneous T-cell lymphoma: how low can you go?","volume":"13","author":"Patel","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111292_b0160","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:38:22Z","timestamp":1770269902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402505296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"alternative-id":["S016781402505296X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111292","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy dose\u2013response of mycosis fungoides with large cell transformation","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111292"}}